{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076553","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.335825+00:00","generated_at":"2026-05-15T23:33:50.155122+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Personalis reports 400% clinical test volume growth in 2025, guides $78-80M FY2026 revenue","bullets":["Clinical volume surged 400% YoY to 16,233 tests; Q4 sequential growth 41% to 6,183 tests.","Total FY2025 revenue $69.6M (down 18% YoY); clinical test revenue more than doubled to $2.0M.","Ended 2025 with ~$240M cash, including $109M net from ATM at $8.43/share average.","Secured Medicare coverage for breast and lung cancer surveillance; key catalyst for MRD.","FY2026 guidance: total revenue $78-80M, clinical revenue $10-11M (5x growth), net loss ~$105M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076553","json":"https://secwatch.observer/filing/0001193125-26-076553.json","markdown":"https://secwatch.observer/filing/0001193125-26-076553.md","text":"https://secwatch.observer/filing/0001193125-26-076553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000119312526076553/0001193125-26-076553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000119312526076553/psnl-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:33:50.155122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}